Clinical Trials Directory

Trials / Completed

CompletedNCT04534712

Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTLYMPHOCYTE MONOCYTE RATIOAbsolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.

Timeline

Start date
2020-09-01
Primary completion
2021-10-01
Completion
2021-10-01
First posted
2020-09-01
Last updated
2023-04-03

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT04534712. Inclusion in this directory is not an endorsement.

Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19 (NCT04534712) · Clinical Trials Directory